^
Association details:
| Biomarker: | CD74-ROS1 fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case report: A novel reciprocal ROS1-CD74 fusion in a NSCLC patient partially benefited from sequential tyrosine kinase inhibitors treatment
Published date:
10/31/2022
Excerpt:
A 44-year-old Chinese woman with a large dimension in the left lobe of the lung was admitted to the hospital with IVB lung adenocarcinoma....the dual CD74-ROS1 fusions were discovered using the RNA next-generation sequencing (NGS) findings….whose progression-free survival was 4 and 5 months for crizotinib treatment and lorlatinib treatment, respectively.
DOI:
10.3389/fonc.2022.1021342
